ArticleBMC complementary medicine and therapies2025
Effects of enhanced Melissa officinalis essential oil via carrageenan on mitigating aflatoxin b1-induced cytotoxicity in HT-29 and HEK-293 cells.
Article in BMC complementary medicine and therapies, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAflatoxin B1 (AFB1) is a common contaminant in agricultural and animal-derived products worldwide, representing a significant environmental hazard. Therefore, this study aimed to assess the anti-toxicity effects of enhanced essential oil from Melissa officinalis, through a safe carrageenan, on HT-29 and HEK-293 cells contaminated with AFB1.
methodsSeeds of M. officinalis were cultivated in plastic containers and subsequently treated with 400 ppm carrageenan during the 6–8 leaf developmental stage. Gas chromatography-mass spectrometry (GC/MS) was employed to characterize the bioactive compounds of the essential oil. The cancerous HT-29 and healthy HEK-293 cell lines were exposed to various concentrations of AFB1 (0.5–3 µg/mL), with and without carrageenan-treated M. officinalis essential oil extract at concentrations ranging from 5 to 40 µg/mL. Based on the findings from the MTT assay, 1 µg/mL of AFB1 and 10 µg/mL of the essential oil extract were selected for subsequent analyses, including flow cytometry, reactive oxygen species assessments, and RT-qPCR.
resultsFlow cytometric analysis indicated that AFB1-induced necrosis in healthy HEK-293 cells (13.10%) was significantly greater than in HT-29 cancer cells (2.33%). In contrast, AFB1 elicited a greater degree of early apoptosis (14.80%) and late apoptosis (11.20%) in HT-29 cells compared to HEK-293 cells, which demonstrated 3.86% and 2.26% early and late apoptosis, respectively. A total of nine and fourteen bioactive compounds were detected within the essential oil profiles of control and carrageenan-treated specimens, respectively. The proportions of necrotic and apoptotic HEK-293 and HT-29 cells were diminished following co-treatment with AFB1 and the carrageenan-treated M. officinalis essential oil. Furthermore, the mRNA expression levels of caspase-3, caspase-9, and Bax were found to be elevated in both HT-29 and HEK-293 cells exposed to AFB1, whereas the expression of Bcl-2 and NF-κB genes was reduced compared to the control group. These gene expression changes were reversed by co-treatment with carrageenan-treated M. officinalis essential oil and AFB1. Additionally, AFB1 was observed to induce reactive oxygen species (ROS) in both HT-29 and HEK-293 cells; however, treatment with carrageenan-treated M. officinalis essential oil resulted in a decrease in ROS levels within cells subjected to AFB1 contamination. DISCUSSION: The findings demonstrated that carrageenan treatment increases the overall content of the essential oil in M. officinalis. HT29 cells serve as a human colorectal epithelial (adenocarcinoma) model, frequently utilized in in vitro investigations of mycotoxins, thereby effectively simulating the intestinal and colorectal environment associated with dietary exposure to AFB1. The investigation into the mechanisms by which enhanced M. officinalis essential oil mitigates AFB1-induced cytotoxicity in HT-29 and HEK-293 cells, utilizing carrageenan, represents a promising research area that integrates the antifungal and anti-aflatoxigenic properties of M. officinalis.
conclusionThese findings highlighted the cyto-protective effect of carrageenan-treated M. officinalis essential oil against AFB1-related toxicity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.